Richard Pazdur (FDA)
Three-day FDA adcomm to feature unprecedented review of Merck, Roche and BMS accelerated approvals
The FDA is continuing its review of cancer drugs that have won accelerated approvals with three days of advisory committee meetings in late April to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
